CREBBP and leukemia: We showed that both pharmacologic inhibition and genetic knockdown of p300 improve the survival of AML1-ETO-bearing mice and that CBP/p300 inhibitors impair the growth of AML1-ETO-expressing (and several other) human leukemia cell lines33.